多可萨赫萨酸 (DHA) 可以缓解由实验性结肠炎引起的炎症和损伤
Leman Arslan Ariturk1, Sumeyye Cilingir2, Meltem Kolgazi2
1Faculty of Medicine, Department of Physiology, Marmara University, Istanbul, Turkey.
European journal of nutrition
|August 6, 2024
概括
在大肠炎模型中,多可萨赫萨酸 (DHA) 显著降低了炎症和氧化应激. DHA治疗改善了肠道屏障功能,可以作为炎症性肠道疾病 (IBD) 的治疗策略.
科学领域:
- 胃肠道学和营养学
- 炎症和氧化应激研究研究
背景情况:
- 炎症性肠病 (IBD),如克罗恩病 (CD) 和性结肠炎 (UC),是导致患者显著发病率的慢性疾病.
- 目前对IBD的治疗策略往往存在局限性,需要探索新型药物.
研究的目的:
- 在化学诱导性结肠炎模型中研究多可萨赫萨酸 (DHA) 在减轻炎症和氧化应激方面的治疗潜力.
- 评估DHA对肠膜透性和屏障功能标记物的影响.
主要方法:
- 在Wistar白鼠中建立了三二硫酸 (TNBS) 诱导性结肠炎模型.
- 动物被用DHA (600毫克/公斤/天) 或液通过管治疗了六周.
- 结肠组织分析了宏观和显微损伤,炎症标志物 (MPO,IL-6,TNF-α),氧化应激标志物 (MDA,GSH,TAS,TOS) 和紧结蛋白 (occludin,ZO-1).
主要成果:
- 由TNBS诱导的结肠炎显著增加了组织损伤,氧化应激和促炎性细胞因子水平,同时降低了抗氧化能力和紧结蛋白表达.
- 服用DHA显著改善了结肠炎引起的损伤,减少了炎症和氧化应激标志物,并恢复了抗氧化剂状态.
- DHA治疗上调了奥克卢丁和ZO-1的表达,表明肠道屏障功能有所改善.
结论:
- 在大肠炎模型中,多可萨赫萨酸 (DHA) 显示出显著的抗氧化和抗炎性质.
- DHA有效地减少反应性氧物种,增强抗氧化能力,并保持肠道粘膜的完整性.
- DHA提高紧结蛋白表达的能力表明其作为IBD治疗剂的潜力.
关键词:
DHA 和 DHA 是什么意思?实验性结肠炎是一种实验性结肠炎.IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD炎症 炎症是一种炎症.肠道屏障 肠道屏障 肠道屏障更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
109
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
109
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124


